Key facts
- This page summarizes Mark Heinen's Form 4 filing for Better Therapeutics, Inc..
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 21 Apr 2023, 18:14.
Mark Heinen - 01 Mar 2023 Form 4 Insider Report for Better Therapeutics, Inc.
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- N/A
- Reported as of
- 01 Mar 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 21 Apr 2023, 18:14:15 UTC
- Prior SEC filing
- 02 Dec 2022
- Next SEC filing
- 19 Dec 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mark Heinen
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Mark Heinen filed Form 4 for Better Therapeutics, Inc. on 21 Apr 2023.
Change
- Previous filing in this sequence was filed on 02 Dec 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BTTX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +54,000
- Change %
- +63%
- Price
- $0.000000
- Shares after
- 139,723
- Date
- 05 Apr 2023
- Ownership
- Direct
- Footnotes
- F1
BTTX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 2,281
- Date
- 01 Mar 2023
- Ownership
- By daughter
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BTTX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +28,550
- Change %
- Price
- $0.000000
- Shares after
- 28,550
- Date
- 01 Mar 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 28,550
- Exercise price
- $1.14
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The shares represent restricted stock units (each, an "RSU") granted on April 5, 2023, which vest as to 1/2 of the shares on March 24, 2024 and the remaining shares vest on March 24, 2025, provided the Reporting Person continues to have a service relationship with Issuer on each vesting date. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
Footnote F2
The stock option vests as to 1/4 of the shares subject to the stock option on March 1, 2024 and the remaining shares vest in 36 equal monthly installments thereafter, provided the Reporting Person continues to have a service relationship with Issuer on each vesting date. The stock option was granted on March 1, 2023.